F-star Therapeutics, Inc. (NASDAQ:FSTX) Receives Average Recommendation of “Moderate Buy” from Analysts

F-star Therapeutics, Inc. (NASDAQ:FSTXGet Rating) has earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $34.33.

Several equities analysts recently commented on FSTX shares. William Blair downgraded F-star Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday. LADENBURG THALM/SH SH downgraded F-star Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday. HC Wainwright started coverage on F-star Therapeutics in a research report on Tuesday, May 17th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Laidlaw downgraded F-star Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday.

Shares of NASDAQ:FSTX traded up $2.37 during trading on Thursday, hitting $6.35. 321,867 shares of the stock were exchanged, compared to its average volume of 136,191. F-star Therapeutics has a 1-year low of $2.07 and a 1-year high of $9.52. The company has a market capitalization of $136.91 million, a price-to-earnings ratio of -4.10 and a beta of 1.84. The company’s fifty day simple moving average is $2.98 and its 200-day simple moving average is $3.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 6.11 and a current ratio of 6.11.

F-star Therapeutics (NASDAQ:FSTXGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.06. The firm had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.30 million. On average, research analysts forecast that F-star Therapeutics will post -2.35 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. acquired a new position in F-star Therapeutics in the first quarter valued at about $48,000. JPMorgan Chase & Co. grew its stake in F-star Therapeutics by 152.7% in the first quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company’s stock valued at $76,000 after acquiring an additional 12,891 shares during the period. Goldman Sachs Group Inc. acquired a new position in F-star Therapeutics in the first quarter valued at about $120,000. State Street Corp grew its stake in F-star Therapeutics by 15.6% in the first quarter. State Street Corp now owns 53,150 shares of the company’s stock valued at $189,000 after acquiring an additional 7,180 shares during the period. Finally, BlackRock Inc. boosted its position in shares of F-star Therapeutics by 1.6% during the first quarter. BlackRock Inc. now owns 295,947 shares of the company’s stock worth $1,050,000 after buying an additional 4,776 shares during the period. 51.67% of the stock is owned by hedge funds and other institutional investors.

F-star Therapeutics Company Profile (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

See Also

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.